Tag: inflammatory diseases

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor^® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsInflammatory diseases

Vincere Portfolios Reports Six Years of Audited Algorithm Performance as Demand Grows for Systematic Investing Solutions

Booking Health Announces Release of Findings on International Access to Personalized Glioblastoma Treatment in Germany

In HelloNation, HVAC Expert Anthony Lane Explains What to Do When an Air Conditioner Stops Working

Tag: inflammatory diseases

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us